Research programme: angiopoietin-like protein 3 inhibitors - Daiichi Sankyo

Drug Profile

Research programme: angiopoietin-like protein 3 inhibitors - Daiichi Sankyo

Alternative Names: ANGPTL 3 inhibitors programme

Latest Information Update: 14 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class
  • Mechanism of Action Angiopoietin inhibitors; Lipoprotein lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Hyperlipidaemia

Most Recent Events

  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo
  • 18 Nov 2003 Preclinical trials in Atherosclerosis in Japan (unspecified route)
  • 18 Nov 2003 Preclinical trials in Hyperlipidaemia in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top